<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30402442</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">2288-6575</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>95</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Annals of surgical treatment and research</Title>                <ISOAbbreviation>Ann Surg Treat Res</ISOAbbreviation>            </Journal>            <ArticleTitle>ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line.</ArticleTitle>            <Pagination>                <MedlinePgn>240-248</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4174/astr.2018.95.5.240</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">This study aimed to validate the synergistic effect of ABT-737 on docetaxel using MDA-MB-231, a triple negative breast cancer (TNBC) cell line overexpressing B-cell lymphoma-2 (Bcl-2).</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Western blot analysis was performed to assess expression levels of Bcl-2 family proteins and caspase-related molecules. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle distribution was determined by flow cytometry analysis. Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (z-VAD-fmk) was used for pretreatment to assess the role of caspases.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Cell viability of MDA-MB-231 after combination treatment with ABT-737 and docetaxel was significantly lower than that after docetaxel or ABT-737 monotherapy based on MTT assay (both P &lt; 0.001), with a combination index of 0.41. The proportion of sub-G1 population after combination treatment was significantly higher than that after docetaxel or ABT-737 monotherapy (P = 0.001, P = 0.003, respectively). Pretreatment with z-VAD-fmk completely restored cell viability of MDA-MB-231 from apoptotic cell death induced by combination therapy (P = 0.001). Although pro-caspase-8 or Bid did not show significant change in expression level, pro-casepase-9 showed significantly decreased expression after combination treatment. Cleaved caspase-3 showed increased expression while poly (ADP-ribose) polymerase cleavage was induced after combination treatment. However, hypoxia-inducible factor 1-alpha and aldehyde dehydrogenase 1 totally lost their expression after combination treatment.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Combination of ABT-737 with docetaxel elicits synergistic therapeutic effect on MDA-MB-231, a TNBC cell line overexpressing Bcl-2, mainly by activating the intrinsic pathway of apoptosis. Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hwang</LastName>                    <ForeName>Eunjoo</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hwang</LastName>                    <ForeName>Seong-Hye</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Jongjin</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Jin Hyun</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oh</LastName>                    <ForeName>Sohee</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biostatistics, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Young A</ForeName>                    <Initials>YA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hwang</LastName>                    <ForeName>Ki-Tae</ForeName>                    <Initials>KT</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0001-6597-3119</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Ann Surg Treat Res</MedlineTA>            <NlmUniqueID>101622895</NlmUniqueID>            <ISSNLinking>2288-6575</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Oct 1;68(19):7985-94</RefSource>                <PMID Version="1">18829556</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jul 11;8(28):45088-45104</RefSource>                <PMID Version="1">28187446</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2010 Nov 11;363(20):1938-48</RefSource>                <PMID Version="1">21067385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2012 Oct 1;131(7):E1109-19</RefSource>                <PMID Version="1">22418857</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63</RefSource>                <PMID Version="1">24355989</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2015 Jan 1;121(1):8-16</RefSource>                <PMID Version="1">25043972</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2016 Apr;156(2):261-9</RefSource>                <PMID Version="1">26975188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2012 Aug 09;3:e366</RefSource>                <PMID Version="1">22875003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2009 May;9(5):321-6</RefSource>                <PMID Version="1">19343035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 Aug 24;103(5):668-75</RefSource>                <PMID Version="1">20664598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2004 Jan 23;116(2):205-19</RefSource>                <PMID Version="1">14744432</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Enzyme Regul. 1984;22:27-55</RefSource>                <PMID Version="1">6382953</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71</RefSource>                <PMID Version="1">21768359</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mutat Res. 2001 Jun 2;477(1-2):97-110</RefSource>                <PMID Version="1">11376691</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Stem Cell. 2007 Nov;1(5):555-67</RefSource>                <PMID Version="1">18371393</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Mar 10;26(8):1275-81</RefSource>                <PMID Version="1">18250347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2012 Jan 26;3:e260</RefSource>                <PMID Version="1">22278287</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Breast Cancer. 2017 Mar;20(1):54-64</RefSource>                <PMID Version="1">28382095</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2016 Aug;16(8):539-48</RefSource>                <PMID Version="1">27364482</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2010 Dec;7(12):683-92</RefSource>                <PMID Version="1">20877296</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2011 Mar;10(3):221-37</RefSource>                <PMID Version="1">21358741</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38</RefSource>                <PMID Version="1">25453096</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2014 Feb 15;20(4):782-90</RefSource>                <PMID Version="1">24536073</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Physiol Rev. 2014 Jan;94(1):1-34</RefSource>                <PMID Version="1">24382882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1984 Nov 30;226(4678):1097-9</RefSource>                <PMID Version="1">6093263</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anal Biochem. 1976 May 7;72:248-54</RefSource>                <PMID Version="1">942051</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2008 May 29;8:153</RefSource>                <PMID Version="1">18510726</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Dec 1;13(23):7191-8</RefSource>                <PMID Version="1">18056200</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</RefSource>                <PMID Version="1">17671126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2009 Oct 15;361(16):1570-83</RefSource>                <PMID Version="1">19828534</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ABT-737</Keyword>            <Keyword MajorTopicYN="N">Bcl-2</Keyword>            <Keyword MajorTopicYN="N">Docetaxel</Keyword>            <Keyword MajorTopicYN="N">Drug resistance</Keyword>            <Keyword MajorTopicYN="N">Triple negative breast neoplasms</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>03</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>04</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30402442</ArticleId>            <ArticleId IdType="doi">10.4174/astr.2018.95.5.240</ArticleId>            <ArticleId IdType="pmc">PMC6204323</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>